Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 6
2007 6
2008 9
2009 7
2010 8
2011 20
2012 23
2013 15
2014 14
2015 5
2016 5
2017 5
2018 4
2019 1
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 22090453

111 results

Results by year

Filters applied: . Clear all
Page 1
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC. Galanis E, et al. J Clin Oncol. 2009 Apr 20;27(12):2052-8. doi: 10.1200/JCO.2008.19.0694. Epub 2009 Mar 23. J Clin Oncol. 2009. PMID: 19307505 Free PMC article. Clinical Trial.
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.
Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, Traynor AM. Hoang T, et al. Invest New Drugs. 2014 Feb;32(1):195-9. doi: 10.1007/s10637-013-9980-5. Epub 2013 Jun 1. Invest New Drugs. 2014. PMID: 23728919 Free PMC article. Clinical Trial.
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. Muscal JA, et al. Pediatr Blood Cancer. 2013 Mar;60(3):390-5. doi: 10.1002/pbc.24271. Epub 2012 Aug 9. Pediatr Blood Cancer. 2013. PMID: 22887890 Free PMC article. Clinical Trial.
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. Schelman WR, et al. Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10. Invest New Drugs. 2013. PMID: 24114121 Free PMC article. Clinical Trial.
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Dimopoulos M, et al. Lancet Oncol. 2013 Oct;14(11):1129-1140. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19. Lancet Oncol. 2013. PMID: 24055414 Clinical Trial.
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. Deming DA, et al. Invest New Drugs. 2014 Apr;32(2):323-9. doi: 10.1007/s10637-013-0035-8. Epub 2013 Oct 10. Invest New Drugs. 2014. PMID: 24114123 Free PMC article. Clinical Trial.
111 results